In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni announce regulatory wins, achieve clinical milestones, appoint new executives, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20). Received FDA Breakthrough Device Designation for its Enhanced Lithotripsy System (ELS), a minimally invasive platform designed to treat kidney stones without general anesthesia, fluoroscopy, or costly capital equipment. The designation accelerates the company’s path to De Novo submission in 2026 and supports its mission to move kidney stone treatments out of the OR and into more accessible outpatient settings.